CEA and Cyfra 21-1 linked to serial miRNA expressions of advanced-stage non-small cell lung cancer in Indonesia

Arif Riswahyudi Hanafi(1*), Achmad Mulawarman Jayusman(2), Priscillia Imelda(3), Serafim Alfasunu(4), Ahmad Hamim Sadewa(5), Dibyo Pramono(6), Didik Setyo Heriyanto(7), Sofia Mubarika Haryana(8), Siti Boedina Kresno(9)

(1) Department of Pulmonology, Dharmais Cancer Hospital, Jakarta
(2) Department of Pulmonology, Dharmais Cancer Hospital, Jakarta
(3) Lung Cancer Research Team, Department of Pulmonology, Dharmais Cancer Hospital, Jakarta
(4) Department of Pulmonology, Dharmais Cancer Hospital, Jakarta
(5) Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada, Yogyakarta
(6) Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada, Yogyakarta
(7) Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada, Yogyakarta
(8) Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada, Yogyakarta
(9) Department of Clinical Pathology, Dharmais Cancer Hospital, Jakarta
(*) Corresponding Author


Globally, lung cancer is one of the cancers leading to dead, dominated by non-small cell lung cancer (NSCLC). In a previous study has shown those serial miRNA expressions (miR-148, miR-34, miR-222, and miR-155) had prognostic value in advanced-stage NSCLC patients. Meanwhile, CEA and Cyfra 21-1, pulmonary tumor markers, are sometimes considered in the Department of Pulmonology, Dharmais Cancer Hospital, Jakarta, although they are not used in routine clinics for prognostication. Both miRNA and CEA-Cyfra 21-1 are valuable biomarkers in NSCLC. This study aimed to evaluate their correlation between CEA and/or Cyfra 21-1 with miRNA expressions in NSCLC patients. It was a cohort retrospective study using data from the previous study. The correlation between variables was analyzed by Spearman-rho. A positive correlation was observed between CEA and Cyfra 21-1 with miR-148, miR-222, and miR-155 [(CEA: p=0.00369, r=0.522; p=0.00242, r=0.542; p 0.00106, r=0.576) (Cyfra: 21-1= p 0.01252, r=0.378; p=0.00035, r=0.519; p=0.01532, r=0.368)]. In conclusion, CEA and Cyfra 21-1 correlate with miR-148, miR-222, and miR-155 expressions in advanced-stage NSCLC.


Advanced stage NSCLC, CEA, Cyfra-21-1, miRNA

Full Text:



1.Global Cancer Observatory (gco.iacr.fr) [Intenet]. Lyon: International Agency for Research of Cancer; ©2022. Cancer today pie chart: Estimated number of new cases in 2020 worldwide, both sexes, all ages [cited 2023 January 23]. Available from: Cancer Today (iarc.fr)
2.American Cancer Society [Internet]. Atlanta: American Cancer Society; ©2022. Key statistic for lung cancer [cited 2023 January 23]. Available from: Lung Cancer Statistics | How Common is Lung Cancer?
3.Kementrian Kesehatan RI [Internet]. Indonesia: Pusat Data dan Informasi Kementrian Kesehatan RI ©2019. Beban Kanker di Indonesia [cited 2023 January 23]. Available from: Infodatin-Kanker-2019.pdf (kemkes.go.id)
4.Guz M, Rivero-Müller A, Okoń E, Stenzel-Bembenek A, Polberg K, Słomka M, et al. MicroRNAs-role in lung cancer. Dis Markers 2014; 2014:218169.
5.Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009; 19(1):92-105.
6.Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 2009; 10(10):704-14.
7.Kosaka N, Iguchi H, Ochiya T. Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Sci 2010; 101(10):2087-92.
8.Schneider J. Tumor markers in detection of lung cancer. Adv Clin Chem 2006; 42:1-41.
9.Kulpa J, Wójcik E, Reinfuss M, Kołodziejski L. Carcinoembryonic antigen, squamous cell carcinoma antigen, CYFRA 21-1, and neuron-specific enolase in squamous cell lung cancer patients. Clin Chem 2002; 48(11):1931-7.
10.Grunnet M, Sorensen JB. Carcinoembryonic antigen (CEA) as tumor marker in lung cancer. Lung Cancer 2012; 76(2):138-43.
11.Tomita M, Shimizu T, Ayabe T, Yonei A, Onitsuka T. Prognostic significance of tumour marker index based on preoperative CEA and CYFRA 21-1 in non-small cell lung cancer. Anticancer Res 2010; 30(7):3099-102.
12.Hanagiri T, Sugaya M, Takenaka M, Oka S, Baba T, Shigematsu Y, et al. Preoperative CYFRA 21-1 and CEA as prognostic factors in patients with stage I non-small cell lung cancer. Lung Cancer 2011; 74(1):112-7.
13.Uchikov A, Dimitrov I, Terzieva D, Mateva N, Kuznanova D, Batashki A. Diagnostic value of the serum tumor markers CEA and CYFRA 21-1 in patients with non-small cell lung cancer. Khirurgiia (Sofiia) 2008; (3):18-20.
14.Muley T, Dienemann H, Ebert W. Increased CYFRA 21-1 and CEA levels are negative predictors of outcome in p-stage I NSCLC. Anticancer Res 2003; 23(5b):4085-93.
15.Hanafi AR, Jayusman AM, Alfasunu S, Sadewa AH, Pramono D, Heriyanto DS, et al. Serum MiRNA as Predictive and Prognosis Biomarker in Advanced Stage Non-small Cell Lung Cancer in Indonesia. Zhongguo Fei Ai Za Zhi 2020; 23(5):321-32.
16.Hanafi AR, Jayusman AM, Imelda P, Alfasunu S, Sadewa AH, Pramono D, et al. Correlation of serum electrolytes with serial miRNA in advanced stage non-small cell lung cancer (NSCLC) in Indonesia. BMC Res Notes 2021; 14(1):437.
17.Kawami M, Takenaka S, Akai M, Yumoto R, Takano M. Characterization of miR-34a-induced epithelial-mesenchymal transition in non-small lung cancer cells focusing on p53. Biomolecules 2021; 11(12):1853.
18.Lu L, Liu Q, Wang P, Wu Y, Liu X, Weng C, et al. MicroRNA-148b regulates tumor growth of non-small cell lung cancer through targeting MAPK/JNK pathway. BMC Cancer 2019; 19(1):209.
19.Brighenti M. MicroRNA and MET in lung cancer. Ann Transl Med 2015; 3(5):68.
20.Zang YS, Zhong YF, Fang Z, Li B, An J. MiR-155 inhibits the sensitivity of lung cancer cells to cisplatin via negative regulation of Apaf-1 expression. Cancer Gene Ther 2012; 19(11):773-8.
21.Hackshaw AK, Law MR, Wald NJ. The accumulated evidence on lung cancer and environmental tobacco smoke. BMJ 1997; 315(7114):980-8.
22.Taylor R, Najafi F, Dobson A. Meta-analysis of studies of passive smoking and lung cancer: effects of study type and continent. Int J Epidemiol 2007; 36(5):1048-59.
23.Yoshimura A, Uchino J, Hasegawa K, Tsuji T, Shiotsu S, Yuba T, et al. Carcinoembryonic antigen and CYFRA 21-1 responses as prognostic factors in advanced non-small cell lung cancer. Transl Lung Cancer Res 2019; 8(3):227-34.
24.Yu Z, Zhang G, Yang M, Zhang S, Zhao B, Shen G, et al. Systematic review of CYFRA 21-1 as a prognostic indicator and its predictive correlation with clinicopathological features in non-small cell lung cancer: A meta-analysis. Oncotarget 2017; 8(3):4043-50.
25.Okamura K, Takayama K, Izumi M, Harada T, Furuyama K, Nakanishi Y. Diagnostic value of CEA and CYFRA 21-1 tumor markers in primary lung cancer. Lung Cancer 2013; 80(1):45-9.
26.Lee JH, Lee SW. The roles of carcinoembryonic antigen in liver metastasis and therapeutic approaches. Gastroenterol Res Pract 2017; 2017:7521987.
27.Dohmoto K, Hojo S, Fujita J, Ueda Y, Bandoh S, Yamaji Y, et al. Mechanisms of the release of CYFRA21-1 in human lung cancer cell lines. Lung Cancer 2000; 30(1):55-63.
28.Liu GL, Liu X, Lv XB, Wang XP, Fang XS, Sang Y. miR-148b functions as a tumor suppressor in non-small cell lung cancer by targeting carcinoembryonic antigen (CEA). Int J Clin Exp Med 2014; 7(8):1990-9.
29.Li X, Xiao H, He R, Chen SH, Chen H. Evaluation of miR-34a, CEA, CA125, and ProGRP combined detection effect in NSCLC diagnosis and prognosis. Int J Clin Exp Med 2019; 12(8):10366-10372.
30.Wadowska K, Błasiak P, Rzechonek A, Bil-Lula I, Śliwińska-Mossoń M. New insights on old biomarkers involved in tumor microenvironment changes and their diagnostic relevance in non-small cell lung carcinoma. Biomolecules 2021; 11(8):1208.

Article Metrics

Abstract views : 170 | views : 190

Copyright (c) 2023 Arif Riswahyudi Hanafi, Achmad Mulawarman Jayusman, Priscillia Imelda, Serafim Alfasunu, Ahmad Hamim Sadewa, Dibyo Pramono, Didik Setyo Heriyanto, Sofia Mubarika Haryana, Siti Boedina Kresno

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

View My Stats


Creative Commons License
Journal of the Medical Sciences (Berkala Ilmu Kedokteran) by  Universitas Gadjah Mada is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Based on a work at http://jurnal.ugm.ac.id/bik/.